Utility of testing for third-generation anticyclic citrullinated peptide (anti-CCP3) antibodies in individuals who present with new musculoskeletal symptoms but have a negative second-generation anticyclic citrullinated peptide (anti-CCP2) antibody test

Di Matteo, A. orcid.org/0000-0003-0867-7051, Mankia, K. orcid.org/0000-0002-7945-6582, Garcia-Montoya, L. et al. (5 more authors) (2024) Utility of testing for third-generation anticyclic citrullinated peptide (anti-CCP3) antibodies in individuals who present with new musculoskeletal symptoms but have a negative second-generation anticyclic citrullinated peptide (anti-CCP2) antibody test. RMD Open, 10 (2). e003927. ISSN 2056-5933

Abstract

Metadata

Item Type: Article
Authors/Creators:
Copyright, Publisher and Additional Information:

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Dates:
  • Published: April 2024
  • Published (online): 10 April 2024
  • Accepted: 22 February 2024
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Inflammatory Arthritis (Leeds)
The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 29 May 2024 10:45
Last Modified: 29 May 2024 10:45
Status: Published
Publisher: BMJ
Identification Number: 10.1136/rmdopen-2023-003927
Related URLs:
Open Archives Initiative ID (OAI ID):

Download

Export

Statistics